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Acute myeloid leukemia (AML) is a heterogeneous, highly malignant neoplasm. Apoptosis is a complex process executed by caspases 
and suppressed by the inhibitor of apoptosis (IAP) family. Neuronal apoptosis inhibitory protein (NAIP), IAP’s member, may play an ex-
ceptional role in the mechanisms of tumors’ resistance to chemotherapy. The aims of the study were to assess the expression of NAIP in 
leukemic blasts of AML patients using flow cytometry and to evaluate its influence on disease outcome. NAIP expression was found in 
106 out of 108 patients. A higher complete response rate was associated with a low expression of NAIP, age < 60 yo, and white blood cell 
count < 20 G/L (p = 0.009, p = 0.033, and p = 0.076, respectively) in univariate analyses and a low NAIP expression and age < 60 yo (p = 
0.025 and p = 0.013, respectively) in multivariate analyses. Longer overall survival (OS) in the univariate analysis was influenced by a low 
NAIP expression, age < 60 yo, and intensive chemotherapy (p = 0.033, p < 0.001, and p < 0.001, respectively). In the intensively treated 
group, better OS was observed in patients with age < 60 yo, de novo AML, and a low NAIP expression (p = 0.03, p = 0.024, and p = 0.07, 
respectively). In multivariate analysis, longer OS was associated with age < 60 yo (p = 0.009) and de novo AML (p = 0.007). In conclusion, 
we suggest that NAIP might play an adverse role in response to chemotherapy.
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Introduction
Acute myeloid leukemia (AML) is an infrequent (1.3%), highly malignant 
neoplasm responsible for a large number of cancer-related deaths [1, 
2]. In the USA and other highly developed countries, the incidence has 
been near stable over the last years and is about 4 cases per 100,000 
citizens per year [1, 2, 3]. The median age at diagnosis is 67 years 
[1–3]. AML is a heterogeneous and complex disease in which genomic 
and proteomic alterations and the interactions between them result in 
various apoptosis abnormalities [1–3].
Apoptosis, programmed cell death, is a highly regulated cellular 
signaling pathway important for normal development that is needed for 
the correct functioning of diverse processes such as embryogenesis 
and tissue homeostasis, as well as tumorigenesis in multicellular 
organisms [4]. The apoptotic signaling cascades can be initiated by 
various extracellular (extrinsic pathway) or intracellular (intrinsic 
pathway) stimuli. Apoptosis is executed by a family of cysteine 
proteases known as caspases, which are produced in cells as inactive 
zymogens and become active proteases subsequent to proteolysis 
[5–8]. Once active, caspases cleave a limited number of substrates 
that result in the destruction of the cells and their eventual disposal by 
phagocytic cells.
The inhibitors of apoptosis (IAP) are a family of proteins comprising 
intrinsic negative regulators of the caspase cascade; these are the 
only known endogenous proteins that interfere with the activity of both 
initiator (caspases 8 and 9) and effector enzymes (caspases 3, 6, and 
7) [9–11]. Eight human IAP family members have been recognized: 
neuronal apoptosis inhibitory protein (NAIP), X-linked inhibitors of 
apoptosis protein (XIAP), cellular inhibitors of apoptosis protein 1 
(cIAP1), cellular inhibitors of apoptosis protein 2 (cIAP2), survivin, 
baculoviral IAP repeat-containing ubiquitin-conjugating enzyme 
(BRUCE/apollon), livin (ML-IAP, KIAP) and IAP-like protein 2 (ILP-2) 
[10]. Various IAP family members have been shown to influence the 
outcome of AML, either alone or in combination [12–15]. It has been 
demonstrated that overexpression of IAP family members in AML 
leukemic cells correlates with a low complete remission (CR) rate 
and shorter overall survival (OS) [16–18]. Especially, a high survivin 
protein expression is associated with shorter OS [16]. Studies on 
XIAP have shown that its overexpression was associated with a lower 
CR rate and worse OS as compared to the in patients with absent or 
low XIAP expression [17,18]. Various levels of IAP family member 
expression have been described in AML patients. Simultaneously, a 
high expression of 1, 2, 3, and 4 proteins has been found to be strongly 
correlated with CR rates 71%, 60%, 57%, and 33%, respectively [16]. 
Additionally, absent or a low expression of all examined proteins (XIAP, 
cIAP1, cIAP2, and survivin) was associated with 100% CR rate [16]. 
These results demonstrate that apoptosis resistance is very complex 
in AML patients.
NAIP is comprised of three 3 zinc-binding baculovirus IAP repeat 
(BIR) domains and, uniquely among IAPs, a nucleotide-binding and 
oligomerization (NOD) domain and a leucine-rich repeat (LRR) domain 
[10, 19]. NAIP has emerged as an important regulator of innate immune 
signaling [20]. Overexpression of this protein has been described in 
inflammatory disorders such as neurodegenerative disorder spinal 
muscular atrophy (SMA) [21]. NAIP is also responsible for the 
intracellular recognition of flagellin, the main structural component of the 
bacterial flagellum. It takes part in the formation of the inflammasome, 
multiprotein oligomer responsible for the activation of inflammatory 
responses. This process activates procaspese-1 cleavage and the 
extracellular secretion of proinflammatory interleukins: IL-1 and IL-18 
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[22]. NAIP also has the same antiapoptotic function as other IAPs. 
Apoptosis inhibition takes place via blockade of caspases 3, 7, 
and 9 [20, 21]. All these processes suggest that NAIP possesses 
unique activity, which might be due to highly variable region of the 
chromosome (5q13) that encodes NAIP.
The overexpression of NAIP has been described in inflammatory 
diseases, motor neurons in SMA, multiple sclerosis, Alzheimer’s 
and Parkinson’s diseases. Moreover, the presence of NAIP has 
been noted in some malignancies, including hematological ones: 
lymphomas, myelodysplastic syndromes (MDS), and AML cells 
[23–26]. The highest expression was noticed in AML refractory to 
chemotherapy [25].
Studies on NAIP expression suggest that it may play an exceptional 
role in neoplasms, including leukemia; however, little information 
exists about its exact role in AML.
Hence, the present study examines the expression of NAIP protein 
and its influence on treatment outcome and survival of AML patients.
Materials and methods
Patients
The study involved 108 patients with newly diagnosed AML who 
were hospitalized between January 2008 and December 2012 in 
the Department of Hematology, Medical University of Lodz. The 
characteristics of the patients are summarized in table I. The study 
was approved by the Ethics Committee of the Medical University of 
Lodz. Written informed consent was obtained from all the patients.
The diagnosis was based on the World Health Organization 
classification of hematopoietic and lymphoid tissues [3]. Median age 
of the patients was 61 years (ranged from 18 to 87 years).
Forty-nine patients received intensive induction chemotherapy 
according to the Polish Adult Leukemia Group (PALG) protocols 
[27, 28]. Fourteen patients received DA daunorubicin and cytarabine 
(DA) induction treatment, while 35 received daunorubicin, cytarabine, 
and cladribine (DAC). Fifty-nine patients received non-intensive 
treatment, 23 patients were treated with low-dose cytarabine (LD-
AraC), 8 with azacitidine (AZA), and 22 with hydroxyurea (HU). Six 
patients underwent best supportive care (BSC) only.
Response to the treatment was defined in accordance with the 
revised recommendations of the International Working Group 
for Diagnosis, Standardization of Response Criteria, Treatment 
Outcomes, and Reporting Standards for Therapeutic Trials in Acute 
Myeloid Leukemia [3, 24]. Briefly, complete response (CR) was 
defined as the presence of less than 5% of bone marrow (BM) blasts 
with a neutrophil count higher than 1.0 G/L, a platelet count higher 
than 100 G/L, and no extramedullary disease. Partial remission (PR) 
was established with either 5–25% BM blasts, a 50% or a higher 
decrease in BM blasts, or BM blasts < 5% but with the presence of 
Auer rods. No response (NR) was established for the patients who 
did not fulfill any of the abovementioned criteria. Early death (ED) 
was defined as a death from any cause within 4 weeks after the 
induction therapy and was considered as treatment failure. Disease-
free survival (DFS) was calculated from the first day of CR until 
documentation of a relapse [3]. OS was calculated from the time of 
diagnosis until death [3].
Laboratory tests
Blood and BM sampling
Venous blood or BM samples were collected at the time of diagnosis 
into pyrogen-free ethylenediaminetetraacetic acid (EDTA) tubes. 
Immunophenotyping of leukemic cells was performed routinely in 
the whole peripheral blood or BM using flow cytometry: the “lysed-
not washed” method. A routine panel of monoclonal antibodies 
HLA-DR, CD34, CD45, CD13, CD15, CD33, and CD117 conjugated 
with fluorescein isothiocyanate (FITC) and phycoerythrin (PE) was 
applied (all BD Pharmingen, San Diego, CA, USA).
Assessment of expression of NAIP protein
Peripheral blood or BM mononuclear cells were isolated from EDTA 
samples by centrifugation on a Histopaque-1077 (Sigma Diagnostics, 
St Louis, MO, USA) density gradient for 30 minutes at 3600 rpm. 
The interphase region containing mononuclear cells was collected 
and washed, once in Hanks’ Balanced Salt Solution (Biomed, Lublin, 
Poland) and twice in phosphate-buffered saline (PBS; Sigma-Aldrich 
Chemie GmbH, Steinheim, Germany). Then, the samples were fixed 
in 1% paraformaldehyde (PFA) (15 minutes at 4°C) and 90% ethanol 
for 30 minutes at -20°C for the flow cytometry analysis.
Flow cytometry cell preparation
The frozen cells were washed in PBS, centrifuged (5 minutes, 
1100 rpm), and incubated in 0.01% saponin for 1 minute. The cells 
were then washed in PBS and centrifuged (5 minutes, 1100 rpm). 
The incubation with primary antibody (Ab) at a dilution of 1:50 
of anti-NAIP (AF 829, polyclonal rabbit anti-human Ab IgG; R&D 
Table I. Patient characteristics
Number of patients n = 108






Median WBC, range, G/L 15.6 (0.67–408)
Median LDH, range, U/L 399 (119–2936)
































WBC – white blood cells; LDH – lactate dehydrogenase; BM – bone marrow; 
AML – acute myeloid leukemia; SWOG – Southwest Oncology Group; DA – 
daunorubicin and cytarabine; DAC – daunorubicin, cytarabine, and cladribine; 
LD-AraC – low-dose cytarabine; HU – hydroxyurea; BSC – best supportive care
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System, Minneapolis, MN, USA) was performed at 4°C overnight. 
On the following day, the samples were washed in PBS, centrifuged 
(5 minutes, 1100 rpm), and incubated for 120 minutes with secondary 
FITC-conjugated Abs at a dilution of 1:20. Afterwards, the samples 
were washed in PBS, centrifuged (5 minutes, 1100 rpm) before being 
resuspended in 400 µL PBS, and subjected to the flow cytometry 
analysis. At the same time, samples with isotype controls were also 
prepared (normal rabbit IgG control, 1:100 dilution; R&D System, 
Minneapolis, MN, USA). All preparations have been previously 
described in detail [16, 30].
Flow cytometry analysis
All fluorescence measurements were performed by the use of flow 
cytometry (FACScan; Becton-Dickinson, San Jose, CA, USA). An 
acquisition gate was established based on forward scatter (FSC) and 
side scatter (SSC) that included mononuclear cells according to the 
previous immunophenotype. Cell fluorescence was measured using 
standard emission filters: FL1 (green, λ 515–545 nm) and FL2 (orange, 
λ 564–606 nm). For each analysis, 10,000 events were acquired and 
analyzed using CellQuestPro software (Becton Dickinson, San Jose, 
CA, USA). Expression of NAIP was presented as a percentage of 
NAIP-positive cells in the whole population of leukemic blasts. All the 
flow cytometry measurements were performed on 10,000 cells per 
sample. The population of NAIP-positive cells was identified after 
gating based on appropriate isotype controls. For data quantitation, 
FACS DIVA software was used. “High” and “low” expression were 
established according to the median of NAIP-positive cells estimated 
in the whole group of patients. Examples of flow cytometry images 
are presented in Figure 1.
Statistical analysis
The statistical analysis was performed with Statistica 12.0 (Tulusa, 
OK, USA) software. Correlations between the variables were 
assessed using the Spearman rank test. OS was estimated using the 
Kaplan–Meier method. The chi-square and logistic regression tests 
were applied to investigate the dependence between individual factors 
and CR rate. The log-rank test was used to evaluate the univariate 
effects of particular variables on OS. For the multivariate analysis of 
factors affecting OS, the Cox proportional hazard regression model 
was applied. Comparisons and correlations between the examined 
parameters were considered as significant when p was < 0.05.
Results
Intracellular flow cytometry protein expression
NAIP protein expression was found in 106 of 108 (98%) newly 
diagnosed AML patients. Median expression was 11.9% (range 
1–79.6%).
NAIP expression and treatment outcome
Response to the treatment
Thirty-three (67%) of 49 intensively treated patients achieved CR. 
The univariate analysis found age below 60 yo, white blood cell 
(WBC) count < 20 G/L and a low expression of NAIP protein to be 
associated with a higher probability of CR achievement (p = 0.033, 
p = 0.076, and p = 0.009, respectively, Table II).
The multivariate analysis found age below 60 yo and low NAIP protein 
expression to be the only factors associated with a higher probability 
of CR achievement (p = 0.013, and p = 0.025, respectively, Table III).
Overall survival
Median time of OS for the whole cohort of patients was 4.7 months 
(range 0.03–120.6 months). The probability of 5-year survival in our 
cohort was 15.5%. In the univariate log-rank analysis, better OS 
was influenced by age less than 60 yo, intensive therapy and a low 
expression of NAIP protein (p < 0.001, p < 0.001, and p = 0.033, 
respectively, Table IV). In multivariate analysis, intensive treatment 
was the only significant factor associated with longer OS (p < 
Fig. 1. Expression of NAIP in flow cytometry
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0.001, Table V). The analysis of the intensively treated group alone 
showed that better OS was influenced by age < 60 yo and de novo 
AML (p = 0.03 and p = 0.024, respectively, Table IV) and longer 
survival tended to be observed in patients with a low expression of 
NAIP (p = 0.07, Table IV). Additionally, in multivariate analysis, age 
below 60 yo and de novo AML were important for longer OS (p = 
0.009 and p = 0.007, respectively, Table V).
Disease-free survival
Median time of DFS for the whole cohort of patients was 15.5 months 
(range 1.8–119 months). The probability of a 5-year DFS in the 
intensively treated cohort was 55%. Age < 60 yo was the only factor 
that influenced longer DFS (p = 0.016).
Relationship between the expression of NAIP protein and 
standard AML risk factors
Expression of NAIP protein in leukemic blasts did not differ 
significantly in the risk groups divided according to age (< 60 yo vs. 
≥ 60 yo), karyotype (good, intermediate, and unknown vs. poor), 
WBC count (≤ 20 G/L vs. >20 G/L), percentage of leukemic blasts in 
BM (≤50% vs. >50%), and lactate dehydrogenase (LDH) (≤UNL, i.e., 
upper normal limit, vs. >ULN).
Discussion
Induction of apoptosis is a crucial process in AML treatment. Identifying 
the factors responsible for cell death inhibition may influence the 
future potential targets for the treatment. NAIP suppressed apoptosis 
by inhibiting initiation of apoptosome formation, which blocked the 
proteolysis of main effector capspases-9, -3, and -7. A literature 
review revealed limited data regarding NAIP expression in AML. 
Tamm et al. studied the expression of IAP family (NAIP, XIAP, cIAP1, 
cIAP2) mRNA in a panel of 60 different human tumor cell lines using 
a real-time reverse transcriptase polymerase chain reaction (RT-
PCR) [15]. They found that NAIP was not detectable in AML cell lines 
(HL60 and RPMI-8226), unlike XIAP, cIAP1, and cIAP2 [15].
Yamamoto et al. using RT-PCR approach described overexpression 
of NAIP mRNA in BM of all examined patients with MDS (n = 13) and 
de novo AML (n = 10) as compared to healthy BM (n = 13) [25]. The 
expression of mRNA of NAIP was almost equal to that of MDS and 
AML cells.
Nakagawa et al. studied NAIP mRNA expression in BM samples from 
13 healthy individuals, 9 patients with AML, 7 with acute lymphoblastic 
leukemia (ALL) and 8 with acute mixed linage leukemia (AMLL) by 
quantitative RT-PCR. They found that NAIP expression was present 
in all examined cases and was higher in AML, ALL, and AMLL than in 
healthy BM samples [26].
Table II. Univariate analysis (chi-square test) of the factors associated with CR rate in intensively treated patients

























































CR – complete remission; AML – acute myeloid leukemia; BM – bone marrow; WBC – white blood cell; LDH – lactate dehydrogenase; UNL– upper normal limit; 
NAIP – neuronal apoptosis inhibitor protein
Table III. Multivariate analysis (logistic regression) of the factors associated with CR rate
Factor CR (95% CI) p-value
Age < 60 yo vs. Age > 60 yo 0.29 (0.12–0.77) 0.013
WBC < 30 G/L vs. WBC > 30 G/L 0.80 (0.38–1.68) 0.56
NAIP < Me vs. NAIP > Me 0.42 (0.19–0.89) 0.025
CR – complete remission; WBC – white blood cell; NAIP – neuronal apoptosis inhibitor protein
A c t a  H a e m a t o l o g i c a  P o l o n i c a
78
The present study is the first to assess the expression of NAIP protein 
in AML cells using cytometry. It identified NAIP expression in 98% of 
AML patients with a range 1–79.6%. The presence of NAIP mRNA 
and protein expression in leukemic cells suggests that it may be an 
important factor for escape from cell death.
Although various IAP family members have been shown to have 
an impact on CR achievement and survival in AML patients [15, 
16], no data have been presented regarding the influence of NAIP 
protein on treatment outcome and survival; however, the univariate 
and multivariate analyses in the present study indicate that a low 
expression of NAIP was associated with a higher CR rate in AML 
(85% vs. 47%; p = 0.009 and p = 0.025, respectively). Moreover, 
a low NAIP protein expression was associated with longer survival 
in the whole group and a trend was observed toward better OS in 
intensively treated patients (p = 0.033 and p = 0.07, respectively). 
The influence of NAIP expression on AML outcome suggests that it 
modulates leukemic cell survival.
Choi et al. measured mRNA NAIP expression in 117 breast cancers 
and 10 normal breast tissues using RT-PCR [31]. NAIP was present 
in all breast samples. It was overexpressed in the cancer tissue as 
compared to healthy breast tissue, and particularly a high expression 
was observed in patients with unfavorable risk factors [31]. The 
authors did not find any correlation between NAIP expression and 
3-year relapse-free survival. However, it should be mentioned that 
this is quite a short period of time in breast cancer patients, and 
the authors underline that longer observation in larger patients’ 
group is necessary to determine the role of NAIP in breast cancer. 
Nevertheless, these findings regarding the significant role of NAIP 
Table IV. Factors associated with the probability of 5-year survival (univariate analysis: log-rank test)
Probability of five-year survival

















0.36 48.3% (33.1%; 70.4%)
11.8% (3.2%; 43.2%)
0.024

















































0.033 42.9% (27.9%; 65.7%)
19.0% (7.9%; 46.0%)
0.07
NA – not applicable; AML – acute myeloid leukemia; SWOG – Southwest Oncology Group; BSC – best supportive care; WBC – white blood cells; BM – bone 
marrow; LDH – lactate dehydrogenase; NAIP – neuronal apoptosis inhibitor protein
Table V. Multivariate analysis (Cox model) of the factors associated with the decreased probability of OS
Factor Whole group Intensively treated group
HR (95% CI) p-value HR (95% CI) p-value
Age < 60 years 1.138 (0.545; 2.379) 0.730 0.290 (0.114; 0.734) 0.009
AML de novo 0.997 (0.621; 1.601) 0.991 0.355 (0.167; 0.752) 0.007
Therapy – intensive 0.233 (0.106; 0.515) 0.0003
NAIP ≤ Me 0.956 (0.598; 1.530) 0.852123 0.688 (0.327; 1.449) 0.326
OS – overall survival; AML – acute myeloid leukemia; NAIP – neuronal apoptosis inhibitor protein
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are supported by a previous study suggesting that NAIP might 
be responsible for the resistance of MCF-7 cell line to bleomycin 
treatment and that NAIP was shown to be downregulated by tumor 
suppressor p53 [32].
Chiu et al. showed using RT-PCR and Western blot approaches that 
NAIP mRNA and protein were expressed in prostatic cancer cells 
[32]. Moreover, the authors observed that increased NAIP expression 
significantly lowered the response to androgen therapy in an in vitro 
and in vivo mouse model [32]. It also corresponded with increased 
DNA-binding activity of NF-kappaB, an NAIP up-regulator, and 
resulted in treatment resistance [32]. In addition, a Spanish group 
studied NAIP expression in 95 patient samples of prostatic cancer 
and 35 cases of benign prostatic hyperplasia as well as 10 normal 
prostatic cells using immunohistochemistry. NAIP protein was present 
only in samples with prostatic neoplasm, and this protein expression 
was in more than 60% of cells [33]. Normal prostatic cells displayed 
a lack of NAIP protein expression; unfortunately, NAIP expression 
was not correlated with clinical and pathological parameters [34]. 
Nevertheless, studies on prostate cancer suggest the NAIP may play 
a role in carcinogenesis.
Additionally, the expression of IAP family members (XIAP, cIAP1, 
and NAIP) was found to increase with carcinoma stage in a hamster 
model of squamous-cell carcinogenesis. Simultaneous RT-PCR 
assessment of p53 mutation and IAP methylation suggests that 
IAP expression might be modulated by both genetic (mutant p53) 
and epigenetic mechanisms [35]. This observation suggests that 
combined treatment may be a future therapeutic option.
Our results are convergent with those in breast and prostatic 
cancer. Higher expression of NAIP is an adverse prognostic factor in 
treatment outcome and survival of AML patients.
Currently, based on the knowledge about IAP’s family, 2 types of 
mechanisms are under investigation in phase I and II of clinical trials 
in the cancer patients. One is based on proapoptotic Smac small 
molecule, which binds IAP’s members and promotes activation of 
caspases leading to apoptosis [35]. The second mechanism uses 
pan-IAP inhibitor. The blockade of IAP’s members induces cleavage 
of caspases 3 and 8 and activates apoptosis [36]. We may expect the 
development of the targeting treatment focusing on IAP’s pathway in 
near future.
Conclusions
NAIP may play an important role in the response to chemotherapy 
and development of refractory disease. However, further studies are 
necessary to establish its exact role in the treatment of AML patients.
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